MNTC Stock Overview
Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mentice AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 21.00 |
| 52 Week High | SEK 71.40 |
| 52 Week Low | SEK 20.00 |
| Beta | 1 |
| 11 Month Change | -28.81% |
| 3 Month Change | -25.27% |
| 1 Year Change | -52.27% |
| 33 Year Change | -79.51% |
| 5 Year Change | -73.88% |
| Change since IPO | -68.93% |
Recent News & Updates
Recent updates
Mentice AB (publ) (STO:MNTC) Just Reported, And Analysts Assigned A kr43.67 Price Target
Nov 11
Mentice AB (publ)'s (STO:MNTC) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors
Aug 31Mentice AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jul 26Investors Still Waiting For A Pull Back In Mentice AB (publ) (STO:MNTC)
Jul 11These Analysts Think Mentice AB (publ)'s (STO:MNTC) Sales Are Under Threat
May 09Mentice AB (publ) Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
May 08Mentice AB (publ) (STO:MNTC) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
Feb 17Capital Allocation Trends At Mentice (STO:MNTC) Aren't Ideal
Feb 03Mentice AB (publ)'s (STO:MNTC) Shares Climb 29% But Its Business Is Yet to Catch Up
Jan 03Is There An Opportunity With Mentice AB (publ)'s (STO:MNTC) 45% Undervaluation?
Dec 21Mentice (STO:MNTC) Will Be Hoping To Turn Its Returns On Capital Around
Oct 04Is There An Opportunity With Mentice AB (publ)'s (STO:MNTC) 42% Undervaluation?
Jan 31Mentice AB (publ) (STO:MNTC) Shares Could Be 44% Below Their Intrinsic Value Estimate
Jun 15Why Mentice AB (publ) (STO:MNTC) Could Be Worth Watching
Apr 19Mentice AB (publ)'s (STO:MNTC) Intrinsic Value Is Potentially 59% Above Its Share Price
Feb 01Is Mentice AB (publ) (STO:MNTC) Potentially Undervalued?
Nov 22Does This Valuation Of Mentice AB (publ) (STO:MNTC) Imply Investors Are Overpaying?
Oct 06Companies Like Mentice (STO:MNTC) Can Afford To Invest In Growth
Sep 03We're Not Very Worried About Mentice's (STO:MNTC) Cash Burn Rate
May 03Calculating The Intrinsic Value Of Mentice AB (publ) (STO:MNTC)
Mar 22Could The Mentice AB (publ) (STO:MNTC) Ownership Structure Tell Us Something Useful?
Feb 15Did Mentice's (STO:MNTC) Share Price Deserve to Gain 10%?
Jan 18Need To Know: Mentice AB (publ) (STO:MNTC) Insiders Have Been Buying Shares
Dec 28
Are Investors Undervaluing Mentice AB (publ) (STO:MNTC) By 20%?
Dec 07Shareholder Returns
| MNTC | SE Healthcare Services | SE Market | |
|---|---|---|---|
| 7D | -16.0% | -4.4% | -3.6% |
| 1Y | -52.3% | 48.3% | 12.3% |
Return vs Industry: MNTC underperformed the Swedish Healthcare Services industry which returned 50.5% over the past year.
Return vs Market: MNTC underperformed the Swedish Market which returned 13.4% over the past year.
Price Volatility
| MNTC volatility | |
|---|---|
| MNTC Average Weekly Movement | 6.8% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: MNTC has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: MNTC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 133 | Göran Malmberg | www.mentice.com |
Mentice AB (publ) provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas. The company operates through three segments: Systems, Software Licenses and Service. It offers software modules in the areas of acute ischemic stroke intervention, atrial septal defect and patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee intervention, carotid intervention, patient-specific simulation, coronary advanced, essential, and intermediate, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic artery embolization, radiation safety, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, peripheral angiography, and vascular trauma and cardiac rhythm management, as well as supports interventionalists to transition from transfemoral to transradial access.
Mentice AB (publ) Fundamentals Summary
| MNTC fundamental statistics | |
|---|---|
| Market cap | SEK 536.95m |
| Earnings (TTM) | -SEK 23.28m |
| Revenue (TTM) | SEK 276.06m |
1.9x
P/S Ratio-23.1x
P/E RatioIs MNTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNTC income statement (TTM) | |
|---|---|
| Revenue | SEK 276.06m |
| Cost of Revenue | SEK 32.73m |
| Gross Profit | SEK 243.33m |
| Other Expenses | SEK 266.61m |
| Earnings | -SEK 23.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 88.15% |
| Net Profit Margin | -8.43% |
| Debt/Equity Ratio | 0% |
How did MNTC perform over the long term?
See historical performance and comparison